Positive News SentimentPositive NewsNASDAQ:ZIMV ZimVie (ZIMV) Stock Forecast, Price & News $9.67 +0.08 (+0.83%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$9.51▼$9.7650-Day Range$9.59▼$14.1252-Week Range$5.05▼$15.50Volume104,175 shsAverage Volume464,707 shsMarket Capitalization$256.55 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ZimVie MarketRank™ ForecastAnalyst RatingSell1.00 Rating ScoreUpside/Downside13.8% Upside$11.00 Price TargetShort InterestHealthy1.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth32.81%From $0.64 to $0.85 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 starsMedical Sector787th out of 968 stocksDental Equipment & Supplies Industry4th out of 5 stocks 1.5 Analyst's Opinion Consensus RatingZimVie has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, ZimVie has a forecasted upside of 13.8% from its current price of $9.67.Amount of Analyst CoverageZimVie has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.97% of the float of ZimVie has been sold short.Short Interest Ratio / Days to CoverZimVie has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ZimVie has recently increased by 4.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldZimVie does not currently pay a dividend.Dividend GrowthZimVie does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZIMV. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for ZimVie this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZimVie insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.01% of the stock of ZimVie is held by insiders.Percentage Held by Institutions85.16% of the stock of ZimVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for ZimVie are expected to grow by 32.81% in the coming year, from $0.64 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ZimVie is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ZimVie is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZimVie has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ZimVie (NASDAQ:ZIMV) StockZimVie Inc., a medical technology company, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; hardware and software solutions consist of intraoral scanners and RealGUIDE; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.Read More ZIMV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZIMV Stock News HeadlinesSeptember 11, 2023 | finance.yahoo.comHere’s Why ZimVie (ZIMV) Advanced in Q2September 8, 2023 | fool.comZimVie (NASDAQ: ZIMV)September 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 31, 2023 | msn.comZimVie (ZIMV) Price Target Increased by 57.14% to 11.22August 17, 2023 | msn.comZimVie expands cooperation with Brainlab on systems compatibility, co-marketingAugust 17, 2023 | finance.yahoo.comZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-MarketingAugust 11, 2023 | msn.comFDA approves smaller height of Mobi-C artificial discs for cervical replacementAugust 10, 2023 | msn.comZimVie gains on FDA nod for new Mobi-C cervical disc implantSeptember 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 10, 2023 | finance.yahoo.comZimVie Announces FDA Approval for New Mobi-C® ImplantAugust 10, 2023 | finance.yahoo.comWhy Fast-paced Mover ZimVie Inc. (ZIMV) Is a Great Choice for Value InvestorsAugust 8, 2023 | markets.businessinsider.comBarclays Maintains Underweight Rating for ZimVie: Here's What You Need To KnowAugust 6, 2023 | finance.yahoo.comInvestors in ZimVie (NASDAQ:ZIMV) have unfortunately lost 35% over the last yearAugust 3, 2023 | finance.yahoo.comZimVie Reports Second Quarter 2023 Financial Results and Provides Update to Annual GuidanceJuly 15, 2023 | news.yahoo.comHampton Roads residents come in droves for much-needed care at free pop-up clinicJuly 12, 2023 | finance.yahoo.comZimVie to Report Second Quarter 2023 Financial Results on August 2, 2023June 21, 2023 | msn.comZimVie: Downgrade To A Hold On Valuation And FundamentalsJune 2, 2023 | finance.yahoo.comHere’s Why ZimVie (ZIMV) Declined in Q1May 22, 2023 | finance.yahoo.comZimVie to Present at the Stifel 2023 Jaws & Paws ConferenceMay 12, 2023 | msn.comZimVie's Return On Capital Employed InsightsMay 9, 2023 | marketwatch.comDental Allograft Bone Material Market Expectation Surges with Rising Demand With Top Companies | Cowellmedi, ZimVie Inc, StraumannMay 9, 2023 | msn.comBarclays Maintains ZimVie (ZIMV) Underweight RecommendationMay 4, 2023 | benzinga.comZimVie shares are trading higher after the company reported better-than-expected Q1 adjusted EPS and sales results.May 4, 2023 | finance.yahoo.comQ1 2023 ZimVie Inc Earnings CallMay 4, 2023 | finance.yahoo.comZimVie (ZIMV) Q1 2023 Earnings Call TranscriptMay 3, 2023 | finance.yahoo.comZimVie Inc. (ZIMV) Tops Q1 Earnings and Revenue EstimatesMay 3, 2023 | msn.comZimVie Non-GAAP EPS of $0.25 beats by $0.20, revenue of $225.43M beats by $18.43MSee More Headlines Receive ZIMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZimVie and its competitors with MarketBeat's FREE daily newsletter. Email Address ZIMV Company Calendar Last Earnings8/02/2023Today9/22/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZIMV CUSIPN/A CIK1876588 Webwww.zimvie.com Phone303-443-7500FaxN/AEmployees2,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+13.8%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.16) Trailing P/E RatioN/A Forward P/E Ratio15.11 P/E GrowthN/ANet Income$-63,880,000.00 Net Margins-9.27% Pretax Margin-11.94% Return on Equity3.80% Return on Assets1.76% Debt Debt-to-Equity Ratio0.74 Current Ratio2.67 Quick Ratio1.47 Sales & Book Value Annual Sales$913.86 million Price / Sales0.28 Cash Flow$6.40 per share Price / Cash Flow1.51 Book Value$29.08 per share Price / Book0.33Miscellaneous Outstanding Shares26,530,000Free Float25,731,000Market Cap$256.55 million OptionableNot Optionable Beta1.40 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Vafa Jamali (Age 53)Pres, CEO & Director Comp: $1.41MMr. Richard J. Heppenstall (Age 52)Exec. VP, CFO & Treasurer Comp: $749.83kMr. Indraneel Kanaglekar (Age 45)Sr. VP & Pres of Global Dental Comp: $534.5kMs. Rebecca A. Whitney (Age 46)Sr. VP & Pres of Global Spine Comp: $622.97kMr. Benjamin HutsonSr. VP of OperationsSandra SchneiderChief Accounting OfficerMr. Steve RondeauSr. VP & Chief Information OfficerMs. Heather Kidwell (Age 54)Sr. VP, Chief Legal, HR & Compliance Officer and Corp. Sec. Ms. Laura DriscollVP of CommunicationsMr. Michael MinetteSr. VP of Strategy & Corp. Devel.More ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULFulcrum TherapeuticsNASDAQ:FULCEnanta PharmaceuticalsNASDAQ:ENTAAtea PharmaceuticalsNASDAQ:AVIRInozyme PharmaNASDAQ:INZYView All CompetitorsInsiders & InstitutionsBarclays PLCSold 5,411 shares on 9/21/2023Ownership: 0.021%ST Germain D J Co. Inc.Bought 4,688 shares on 9/7/2023Ownership: 0.018%Comerica BankBought 27,708 shares on 8/22/2023Ownership: 0.104%Citadel Advisors LLCBought 3,500 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaBought 1,430 shares on 8/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions ZIMV Stock - Frequently Asked Questions Should I buy or sell ZimVie stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ZimVie in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" ZIMV shares. View ZIMV analyst ratings or view top-rated stocks. What is ZimVie's stock price forecast for 2023? 1 equities research analysts have issued 12 month price objectives for ZimVie's stock. Their ZIMV share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price. View analysts price targets for ZIMV or view top-rated stocks among Wall Street analysts. How have ZIMV shares performed in 2023? ZimVie's stock was trading at $9.34 at the start of the year. Since then, ZIMV shares have increased by 3.5% and is now trading at $9.67. View the best growth stocks for 2023 here. When is ZimVie's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our ZIMV earnings forecast. How were ZimVie's earnings last quarter? ZimVie Inc. (NASDAQ:ZIMV) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.20. The firm had revenue of $224.90 million for the quarter, compared to analyst estimates of $212.36 million. ZimVie had a positive trailing twelve-month return on equity of 3.80% and a negative net margin of 9.27%. What ETF holds ZimVie's stock ? Schwab Ariel ESG ETF holds 1,617 shares of ZIMV stock, representing 0.08% of its portfolio. What guidance has ZimVie issued on next quarter's earnings? ZimVie issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $0.50-$0.70 for the period, compared to the consensus estimate of $0.46. The company issued revenue guidance of $850.00 million-$870.00 million, compared to the consensus revenue estimate of $849.00 million. What is ZimVie's stock symbol? ZimVie trades on the NASDAQ under the ticker symbol "ZIMV." Who are ZimVie's major shareholders? ZimVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.35%), Kent Lake Capital LLC (5.19%), Divisadero Street Capital Management LP (3.77%), Acadian Asset Management LLC (2.54%), State Street Corp (1.83%) and Charles Schwab Investment Management Inc. (1.79%). Insiders that own company stock include Richard Heppenstall, Sally Crawford and Vafa Jamali. View institutional ownership trends. How do I buy shares of ZimVie? Shares of ZIMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ZimVie's stock price today? One share of ZIMV stock can currently be purchased for approximately $9.67. How much money does ZimVie make? ZimVie (NASDAQ:ZIMV) has a market capitalization of $256.55 million and generates $913.86 million in revenue each year. The company earns $-63,880,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. How many employees does ZimVie have? The company employs 2,700 workers across the globe. How can I contact ZimVie? The official website for the company is www.zimvie.com. The company can be reached via phone at 303-443-7500 or via email at marissa@gilmartinir.com. This page (NASDAQ:ZIMV) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.